TABLE OF CONTENTS
1 INTRODUCTION 91
1.1 OBJECTIVES OF THE STUDY 91
1.2 MARKET DEFINITION 91
1.3 OVERVIEW OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET 91
1.4 CURRENCY AND PRICING 94
1.5 LIMITATIONS 94
1.6 MARKETS COVERED 94
2 MARKET SEGMENTATION 98
2.1 MARKETS COVERED 98
2.2 GEOGRAPHICAL SCOPE 99
2.3 YEARS CONSIDERED FOR THE STUDY 100
2.4 DBMR TRIPOD DATA VALIDATION MODEL 101
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 104
2.6 MULTIVARIATE MODELLING 105
2.7 MARKET END USER COVERAGE GRID 106
2.8 PRODUCT LIFELINE CURVE 107
2.9 DBMR MARKET POSITION GRID 108
2.10 VENDOR SHARE ANALYSIS 109
2.11 SECONDARY SOURCES 110
2.12 ASSUMPTIONS 110
3 EXECUTIVE SUMMARY 111
4 PREMIUM INSIGHTS 114
4.1 PESTEL ANALYSIS 115
4.2 PORTERS FIVE FORCES MODEL 116
5 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS 117
6 EPIDEMIOLOGY 119
7 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS 120
8 MARKET OVERVIEW 123
8.1 DRIVERS 125
8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER 125
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS 125
8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 126
8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER 126
8.2 RESTRAINTS 127
8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS 127
8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER 127
8.3 OPPORTUNITIES 128
8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER 128
8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 129
8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS 129
8.4 CHALLENGES 130
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 130
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 130
9 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE 131
9.1 OVERVIEW 132
9.2 IMAGING TEST 135
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 136
9.2.2 MAGNETIC RESONANCE IMAGING (MRI) 136
9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY 136
9.2.2.2 MR ANGIOGRAPHY (MRA) 137
9.2.3 ULTRASOUND 137
9.2.3.1 ABDOMINAL ULTRASOUND 137
9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS) 137
9.2.4 CHOLANGIOPANCREATOGRAPHY 137
9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) 138
9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) 138
9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC) 138
9.2.5 POSITRON EMISSION TOMOHRAPHY (PET) 138
9.2.6 OTHERS 138
9.3 BIOPSY 139
9.3.1 CT-GUIDED NEEDLE BIOPSY 140
9.3.2 FINE NEEDLE ASPIRATION (FNA) 140
9.3.3 CORE NEEDLE BIOPSY 140
9.3.4 OTHERS 140
9.4 BLOOD TEST 140
9.4.1 LIVER FUNCTION TEST 141
9.4.2 TUMOR MARKER 141
9.4.2.1 CA 19-9 BIOMARKER TEST 142
9.4.2.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST 142
9.4.2.3 CA 50 MARKER TEST 142
9.4.2.4 OTHERS 142
9.4.3 OTHERS 142
9.5 GENOMIC TEST 143
9.6 OTHERS 144
10 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 145
10.1 OVERVIEW 146
10.2 STAGE IV 149
10.3 STAGE III 149
10.4 STAGE II 150
10.4.1 STAGE IIA 151
10.4.2 STAGE IIB 151
10.5 STAGE I 151
10.5.1 STAGE IA 152
10.5.2 STAGE IB 152
10.6 STAGE 0 153
11 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 154
11.1 OVERVIEW 155
11.2 EXOCRINE TUMORS 158
11.2.1 INSTRUMENT-BASED PRODUCTS 159
11.2.2 PLATFORM-BASED PRODUCTS 159
11.2.3 KITS AND REAGENTS 159
11.2.4 OTHER CONSUMABLES 159
11.3 NEUROENDOCRINE TUMORS 159
11.3.1 INSTRUMENT-BASED PRODUCTS 160
11.3.2 PLATFORM-BASED PRODUCTS 160
11.3.3 KITS AND REAGENTS 161
11.3.4 OTHER CONSUMABLES 161
12 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT 162
12.1 OVERVIEW 163
12.2 INSTRUMENT-BASED PRODUCTS 166
12.2.1 IMAGING 167
12.2.2 BIOPSY 167
12.3 PLATFORM-BASED PRODUCTS 167
12.3.1 NEXT-GENERATION SEQUENCING 168
12.3.2 MICROARRAYS 168
12.3.3 PCR 168
12.3.4 OTHERS 169
12.4 KITS AND REAGENTS 169
12.4.1 CA19-9 PANCREATIC CANCER TEST KITS 170
12.4.1.1 ELISA TEST KITS 170
12.4.1.2 CASETTE TEST KITS 170
12.4.1.3 OTHERS 170
12.4.2 CEA PANCREATIC CANCER TEST KITS 171
12.4.2.1 ELISA TEST KITS 171
12.4.2.2 CASETTE TEST KITS 171
12.4.2.3 OTHERS 171
12.5 OTHER CONSUMABLES 171
13 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 173
13.1 OVERVIEW 174
13.2 FLUORESCENT IN SITU HYBRIDIZATION 177
13.3 NEXT GENERATION SEQUENCING 178
13.4 FLUORIMMUNOASSAY 179
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 180
13.6 IMMUNOHISTOCHEMICAL 181
13.7 OTHERS 182
14 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 183
14.1 OVERVIEW 184
14.2 SCREENING 187
14.2.1 INSTRUMENT-BASED PRODUCTS 188
14.2.2 PLATFORM-BASED PRODUCTS 188
14.2.3 KITS AND REAGENTS 188
14.2.4 OTHER CONSUMABLES 188
14.3 DIAGNOSTIC AND PREDICTIVE 188
14.3.1 INSTRUMENT-BASED PRODUCTS 189
14.3.2 PLATFORM-BASED PRODUCTS 189
14.3.3 KITS AND REAGENTS 189
14.3.4 OTHER CONSUMABLES 189
14.4 PROGNOSTIC 190
14.4.1 INSTRUMENT-BASED PRODUCTS 191
14.4.2 PLATFORM-BASED PRODUCTS 191
14.4.3 KITS AND REAGENTS 191
14.4.4 OTHER CONSUMABLES 191
14.5 RESEARCH 191
14.5.1 INSTRUMENT-BASED PRODUCTS 192
14.5.2 PLATFORM-BASED PRODUCTS 192
14.5.3 KITS AND REAGENTS 192
14.5.4 OTHER CONSUMABLES 192
15 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 193
15.1 OVERVIEW 194
15.2 HOSPITALS 197
15.3 DIAGNOSTIC CENTERS 197
15.4 CANCER RESEARCH CENTERS 198
15.5 ACADEMIC INSTITUTES 199
15.6 AMBULATORY SURGICAL CENTERS 200
15.7 OTHERS 201
16 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 202
16.1 OVERVIEW 203
16.2 DIRECT TENDER 206
16.3 RETAIL SALES 207
16.4 OTHERS 208
17 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 209
17.1 EUROPE 210
17.1.1 GERMANY 225
17.1.2 FRANCE 234
17.1.3 UNITED KINGDOM 243
17.1.4 ITALY 252
17.1.5 SPAIN 261
17.1.6 RUSSIA 270
17.1.7 NETHERLANDS 279
17.1.8 POLAND 288
17.1.9 SWITZERLAND 297
17.1.10 BELGIUM 306
17.1.11 SWEDEN 315
17.1.12 NORWAY 324
17.1.13 DENMARK 333
17.1.14 FINLAND 342
17.1.15 TURKEY 351
17.1.16 REST OF EUROPE 360
18 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 361
18.1 COMPANY SHARE ANALYSIS: EUROPE 361
19 SWOT ANALYSIS 362
20 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET 363
20.1 CANON MEDICAL SYSTEMS CORPORATION 363
20.1.1 COMPANY SNAPSHOT 363
20.1.2 REVENUE ANALYSIS 363
20.1.3 COMPANY SHARE ANALYSIS 364
20.1.4 PRODUCT PORTFOLIO 364
20.1.5 RECENT DEVELOPMENT 364
20.2 KONINKLIJKE PHILIPS N.V. 365
20.2.1 COMPANY SNAPSHOT 365
20.2.2 REVENUE ANALYSIS 365
20.2.3 COMPANY SHARE ANALYSIS 366
20.2.4 PRODUCT PORTFOLIO 366
20.2.5 RECENT DEVELOPMENTS 366
20.3 SIEMENS HEALTHCARE GMBH 368
20.3.1 COMPANY SNAPSHOT 368
20.3.2 REVENUE ANALYSIS 368
20.3.3 COMPANY SHARE ANALYSIS 369
20.3.4 PRODUCT PORTFOLIO 369
20.3.5 RECENT DEVELOPMENT 370
20.4 GRAIL 371
20.4.1 COMPANY PROFILE 371
20.4.2 COMPANY SHARE ANALYSIS 371
20.4.3 PRODUCT PORTFOLIO 372
20.4.4 RECENT DEVELOPMENT 372
20.5 MYRIAD GENETICS, INC. 373
20.5.1 COMPANY SNAPSHOT 373
20.5.2 REVENUE ANALYSIS 373
20.5.3 COMPANY SHARE ANALYSIS 374
20.5.4 PRODUCT PORTFOLIO 374
20.5.5 RECENT DEVELOPMENT 374
20.6 BD 375
20.6.1 COMPANY SNAPSHOT 375
20.6.2 REVENUE ANALYSIS 375
20.6.3 PRODUCT PORTFOLIO 376
20.6.4 RECENT DEVELOPMENT 376
20.7 BODITECH MED INC. 377
20.7.1 COMPANY PROFILE 377
20.7.2 PRODUCT PORTFOLIO 377
20.7.3 RECENT DEVELOPMENT 377
20.8 ABBOTT (2022) 378
20.8.1 COMPANY SNAPSHOT 378
20.8.2 REVENUE ANALYSIS 378
20.8.3 PRODUCT PORTFOLIO 379
20.8.4 RECENT DEVELOPMENT 379
20.9 FUJIFILM HOLDINGS AMERICA CORPORATION 380
20.9.1 COMPANY SNAPSHOT 380
20.9.2 REVENUE ANALYSIS 380
20.9.3 PRODUCT PORTFOLIO 381
20.9.4 RECENT DEVELOPMENT 381
20.10 ACCUBIOTECH CO., LTD. 382
20.10.1 COMPANY PROFILE 382
20.10.2 PRODUCT PORTFOLIO 382
20.10.3 RECENT DEVELOPMENTS 382
20.11 AGILENT TECHNOLOGIES, INC. 383
20.11.1 COMPANY PROFILE 383
20.11.2 REVENUE ANALYSIS 383
20.11.3 PRODUCT PORTFOLIO 384
20.11.4 RECENT DEVELOPMENT 384
20.12 CREATIVE BIOLABS. 385
20.12.1 COMPANY PROFILE 385
20.12.2 PRODUCT PORTFOLIO 385
20.12.3 RECENT DEVELOPMENT 385
20.13 CTK BIOTECH, INC. 386
20.13.1 COMPANY PROFILE 386
20.13.2 PRODUCT PORTFOLIO 386
20.13.3 RECENT DEVELOPMENT 386
20.14 DIASOURCE 387
20.14.1 COMPANY SNAPSHOT 387
20.14.2 PRODUCT PORTFOLIO 387
20.14.3 RECENT DEVELOPMENT 387

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.